Paper Details

  1. Home
  2. Paper Details

Fluphenazine (oral) versus placebo for schizophrenia.

Author: AlmerieMuhammad Q, MatarHosam E, SampsonStephanie

Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This review examined the effects of oral fluphenazine compared to placebo in seven randomized controlled trials involving 439 participants with schizophrenia. Fluphenazine was found to be a potent antipsychotic but with considerable adverse effects, suggesting that other drugs may be preferable.
Paper Details　
Original Abstract of the Article :
Fluphenazine, a phenothiazine derivative, was one of the first drugs to be classed as an "antipsychotic" and was approved by the Food and Drug Administration in 1959. In Britain, it was first used for the relief of anxiety. The American reports, however, were the first to indicate its value in psych...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3796096/

データ提供：米国国立医学図書館（NLM）

Fluphenazine for Schizophrenia: A Comprehensive Review

Fluphenazine, an antipsychotic medication, has been used for decades to treat schizophrenia. This systematic review examines the effectiveness of oral fluphenazine compared to placebo in treating schizophrenia, analyzing data from seven randomized controlled trials. The review evaluates various outcomes, including global state, relapse rates, and extrapyramidal side effects.

Fluphenazine: Effectiveness and Side Effects in Schizophrenia

This systematic review provides a comprehensive evaluation of the effectiveness of oral fluphenazine in treating schizophrenia. The study suggests that fluphenazine may be effective in reducing relapse rates but also carries a risk of extrapyramidal side effects. The research underscores the need for careful consideration of potential benefits and risks when prescribing this medication for schizophrenia.

Navigating the Desert of Mental Illness

Imagine a vast and challenging desert, symbolizing the complexities of mental illness. This research explores the effectiveness of fluphenazine, an antipsychotic medication, in treating schizophrenia. The study highlights the importance of understanding both the potential benefits and the potential side effects of medications used for this condition, emphasizing the need for careful patient selection and monitoring to optimize treatment outcomes.

Dr.Camel's Conclusion

This systematic review provides a comprehensive evaluation of the effectiveness of oral fluphenazine in treating schizophrenia. The study highlights the potential benefits of the medication in reducing relapse rates but also underscores the importance of considering the potential risks of extrapyramidal side effects. This research encourages further research and careful clinical evaluation of fluphenazine and other antipsychotic medications to optimize treatment strategies and improve patient outcomes.
Date :
  1. Date Completed 2014-06-23
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

24072807

DOI: Digital Object Identifier

PMC3796096

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.